spec sheet10 rows
1cP-AL-LAD is a doubly modified lysergamide carrying a cyclopropanecarbonyl group on the indole nitrogen of AL-LAD (6-allyl-6-nor-LSD), and it was first formally identified in seized blotter products in Japan. By analogy with other N1-acyl lysergamides it is presumed to act as a prodrug that is cleaved in the body to AL-LAD, a colorful 5-HT2A receptor agonist generally described as comparatively short and gentle. Its parent AL-LAD is equipotent to slightly less potent than LSD in the mouse head-twitch assay, whereas the metabolic pathways and biological activity of 1cP-AL-LAD itself have not yet been directly characterized. The available literature is largely forensic and analytical, reflecting its recent and limited emergence on the new psychoactive substance market.
- Strong, colorful visuals
- Often shorter than LSD
- Comparatively gentle headspace
- Doubly modified AL-LAD prodrug lysergamide
- Anxiety possible
- Vasoconstriction
- Insomnia after use
Mechanism
The active molecule works chiefly as an at the receptor, the receptor behind the psychedelic state, with secondary serotonergic activity. The 1-cyclopropanoyl group on the ring nitrogen is thought to be removed after dosing to release AL-LAD, whose allyl substitution tends to make it somewhat more visual and often shorter than LSD. As an obscure analog, its precise potency and receptor profile are not well characterized.
receptor fingerprint
receptoragonist (via AL-LAD)
5-HT2C receptoragonist
receptoragonist
Safetyrisks and cautions, not medical advice
This is a little-studied compound, so exact potency is uncertain; AL-LAD is generally described as fairly gentle and visual but still a real psychedelic. Avoid with a personal or family history of psychosis or bipolar disorder, and never combine lysergamides with MAOIs or strongly serotonergic drugs (serotonin toxicity), or with lithium or tramadol (seizure reports). Not medical advice.
Subjective profileweighing the evidence above
An unmeasured research chemical standing in for AL-LAD; nothing about its own potency or metabolism has been characterized, so a blotter is a guess dressed up as a dose. If a lysergamide is the point, better-mapped ones exist. Never alongside MAOIs, lithium or tramadol.
Resources
This entry is here for reference.
Research
- 2017first citedCrystal Structure of an LSD-Bound Human Serotonin Receptor.
- 2023most recentIdentification of LSD analogs, 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD and LSZ in sheet products.
- 1.Identification of LSD analogs, 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD and LSZ in sheet products.
- 2.Return of the lysergamides. Part II: Analytical and behavioural characterization of N(6) -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ).
- 3.In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures.
- 4.Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD).
- 5.Crystal Structure of an LSD-Bound Human Serotonin Receptor.
- 6.Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor.
6 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
What is AL-LAD like?
It is often described as visually rich but a bit lighter and shorter than LSD; 1cP-AL-LAD is thought to deliver that same parent compound.
Is it well studied?
No; it is an obscure research chemical, so potency and pharmacology are only loosely characterized.
Can I mix it with other psychedelics?
Stacking serotonergic drugs raises risk and unpredictability; be cautious. This is not medical advice.
Adverse effects
- Anxiety possible
- Vasoconstriction
- Insomnia after use
Notes and cautions
- Uncertain potency